Praxis Precision Medicines/$PRAX
1D1W1MYTD1Y5YMAX
Capital at risk
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
- Ticker
- $PRAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 168
- Headquarters
- Boston, United States
- Website
- praxismedicines.com
PRAX Metrics
BasicAdvanced
$9.3B
-
-$12.86
2.78
-
Price and volume
Market cap
$9.3B
Beta
2.78
52-week high
$392.70
52-week low
$37.25
Average daily volume
378K
Financial strength
Current ratio
15.734
Quick ratio
28.639
Long term debt to equity
0.081
Total debt to equity
0.081
Profitability
EBITDA (TTM)
-378.048
Management effectiveness
Return on assets (TTM)
-25.65%
Return on equity (TTM)
-38.86%
Valuation
Price to book
6.96
Price to tangible book (TTM)
6.96
Price to free cash flow (TTM)
-28.824
Free cash flow yield (TTM)
-3.47%
Free cash flow per share (TTM)
-11.608
Growth
Earnings per share change (TTM)
4.28%
3-year earnings per share growth (CAGR)
-33.39%
What the Analysts think about PRAX
Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.
Analyst projections of the future price of Praxis Precision Medicines stock.
Bulls say / Bears say
Completed FDA mid-cycle meetings for ulixacaltamide HCl and relutrigine with no major safety or efficacy concerns, and PDUFA dates set for January 29, 2027 and December 27, 2026, respectively. (Reuters)
Cash and investments amounted to approximately $1.4 billion as of June 30, 2026, which the company expects will fund operations into 2028, reducing near-term capital risk. (Reuters)
Praxis received its third Breakthrough Therapy Designation for elsunersen following positive EMBRAVE Part A trial results, further validating its Solidus ASO platform. (Reuters)
The company reported a net loss of $83.7 million in Q2 2026, up from $71.1 million in the same quarter of last year, reflecting widening operational deficits. (Reuters)
Research and development expenses increased to $69.4 million in Q2 2026 from $63.0 million a year earlier, while general and administrative expenses more than doubled to $27.5 million, driving higher cash burn. (Reuters)
Key value inflection points hinge on regulatory approvals, with PDUFA dates over a year away, exposing the equity to binary outcomes on ulixacaltamide and relutrigine. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
PRAX Financial Performance
Revenues and expenses
PRAX Earnings Performance
Company profitability
Upcoming events
No upcoming events
PRAX News
AllArticlesVideos
Funds containing PRAX
AllUSDGBPEUR
Fund name | Fund size | $PRAX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.58% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.58% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.28% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.11% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.